拉米夫定耐药慢性乙型肝炎患者改用或加用阿德福韦酯治疗48周疗效比较

黄美金; 覃后继; 何延专; 黄其文; 周耀南; 丘海先

doi:10.3969/j.issn.1001-5256.2014.07.015

拉米夫定耐药慢性乙型肝炎患者改用或加用阿德福韦酯治疗48周疗效比较

DOI: 10.3969/j.issn.1001-5256.2014.07.015

百色市右江民族医学院附属医院感染性疾病科

详细信息

中图分类号: R512.62
计量
- 文章访问数: 2518
- HTML全文浏览量: 25
- PDF下载量: 650
- 被引次数: 0
出版历程
- 收稿日期: 2013-08-20
- 出版日期: 2014-07-20

Forty-eight-week efficacy of adefovir dipivoxil alone versus combined with lamivudine in treatment of lamivudine-resistant HBeAg-positive chronic hepatitis B

Department of Infectious Disease, Affiliated Hospital of Youjiang Medical College for Nationalities, Baise

摘要

摘要: 目的观察拉米夫定(LAM)与阿德福韦酯(ADV)联合应用和单用ADV治疗LAM耐药HBeAg阳性慢性乙型肝炎患者的疗效及安全性。方法收集2006年1月至2011年12月在本院就诊的LAM耐药HBeAg阳性慢性乙型肝炎患者40例,单药组与联合组各20例,分别以ADV与LAM联合或单用ADV进行治疗。观察治疗24周、48周时的血清HBV DNA水平及转阴率、HBeAg转阴率、ALT复常率以及治疗过程中药物的不良反应和耐药性。组间比较计量资料采用t检验,计数资料采用卡方检验。结果两组患者在性别、年龄、治疗前的HBV DNA及ALT水平上差异均无统计学意义(P>0.05);治疗结束时联合组的血清HBV DNA转阴率和ALT复常率分别为90%及95%,而单药组的血清HBV DNA转阴率和ALT复常率分别为60%及65%,两组比较差异有统计学意义(P<0.05);治疗结束时联合组血清HBeAg转阴率为45%,单药组为35%,两组比较差异无统计学意义(χ2=0.417,P=0.519)。结论 ADV联合LAM或ADV单药治疗LAM耐药HBeAg阳性慢性乙型肝炎患者均有较好的临床疗效,但A...
- 肝炎,乙型,慢性 /
- 拉米夫定 /
- 阿德福韦酯 /
- 抗药性,病毒
Abstract: Objective To observe the therapeutic efficacy and safety of adefovir dipivoxil (ADV) alone versus combined with lamivudine (LAM) in the treatment of LAM- resistant HBeAg- positive chronic hepatitis B (CHB) . Methods Forty patients with LAM- resistant HBeAg- positive CHB were randomly assigned to monotherapy group (n = 20) and combination therapy group (n = 20) . The monotherapy group received ADV alone, while the combination therapy group received ADV combined with LAM. After 24 and 48 weeks of treatment, serum HBV DNA level, undetectable HBV DNA rate, HBeAg loss rate, alanine aminotransferase ( ALT) normalization rate, adverse reactions, and drug resistance were assessed. The two groups were compared by t- test for continuous data and chi- square test for categorical data. Results There were no significant differences in sex, age, and pretreatment levels of serum HBV DNA and ALT between the two groups (P > 0. 05) . After 48 weeks of treatment, serum undetectable HBV DNA rate and ALT normalization rate for the combination therapy group were 90% and 95%, respectively, significantly higher than those for the monotherapy group (60% and 65%) (P < 0. 05) ; there was no significant difference in HBeAg loss rate between the combination therapy group and monotherapy group (45% vs 35%, χ2= 0. 417, P =0. 519) . Conclusion ADV alone or combined with LAM has good clinical efficacy in the treatment of LAM- resistant HBeAg- positive CHB. However, the combination therapy can increase undetectable HBV DNA rate and ALT normalization rate and has good safety, and it holds promise for clinical application.
- hepatitis B, chronic /
- lamivudine /
- adefovir dipivoxil /
- drug resistance, viral

HTML全文

参考文献(9)

[1]LIAW YF, SUNG JJ, CHOW WC, et al.Lamivudine for patientswith chronic hepatitis B and advanced liver disease[J].N Engl J Med, 2004, 351 (15) :1521-1531.

[2]PERRILLO R, SCHIFF E, YOSHIDA E, et al.Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants[J].Hepatology, 2000, 32 (1) :129-134.

[3] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :Ⅰ-ⅩⅥ. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :Ⅰ-ⅩⅥ.

[4]NI Q, LIU KZ.Current issues of antiviral therapy for chronic hepatitis B[J].J Clin Hepatol, 2012, 28 (3) :172-175. (in Chinese) 倪勤, 刘克洲.慢性乙型肝炎抗病毒治疗若干热点[J].临床肝胆病杂志, 2012, 28 (3) :172-175.

[5]SONG MN, HUANG WQ, MIN F, et al.The efficacy of3 years adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance[J].J Clin Hepatol, 2012, 28 (1) :29-32. (in Chinese) 宋闽宁, 黄文琪, 闵峰, 等.阿德福韦酯单药挽救治疗对拉米夫定耐药的慢性乙型肝炎患者3年疗效观察[J].临床肝胆病杂志, 2012, 28 (1) :29-32.

[6]LI F, LEI FF, LI G, et al.Clinical research of lamivudine and adeforir dipivoxil inital combination therapy for chronic hepatitis B[J].China Med Herald, 2012, 9 (21) :85-86. (in Chinese) 李芳, 雷飞飞, 李刚, 等.拉米夫定和阿德福韦酯初始联合治疗慢性乙型肝炎的临床研究[J].中国医药导报, 2012, 9 (21) :85-86.

[7]ZENG FR, CAI SL, ZHAO WH.Effect of adefovir dipioxil combined with lamivudine in treatment of patients with cirrhosis induced by active hepatitis B[J].J Clin Exp Med, 2013, 12 (22) :1843-1845. (in Chinese) 曾凡荣, 蔡胜蓝, 赵文海.阿德福韦酯联合拉米夫定治疗活动性乙型肝炎肝硬化的临床疗效观察[J].临床和实验医学杂志, 2013, 12 (22) :1843-1845.

[8]BORROTO-ESODA K, ARTERBURNS, SNOWA, et al.483 final analysis of virological outcomes and resistance during 5 years of adefovir dipivoxil monotherapy in HBeAg-negative patients[J].J Hepatology, 2006, 44:s179-s180.

[9]RAPTI I, DIMOU E, MITSOULA P, et al.Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAgnegative chronic hepatitis B[J].Hepatology, 2007, 45 (2) :307-313.

施引文献

资源附件(0)

访问统计